Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lots of good technical information in this post.
Thank you. hL shmn
$SHMN: MPSTOCK: It's NOT your fault. Mktg needs to do a better job.
URGENCY is IMPORTANT.
>>I just don’t see a catalyst right now that will move the price up
1. The CATALYSTS have been clearly communicated 👇️
The company is actively exploring, negotiating, and collaborating with several Japanese companies to expand its business.
— SOHM, Inc. (@sohminc) March 19, 2024
This expansion includes the utilization of gene-editing technology called ABBIE, as well as licensing opportunities.
The management remains committed to…
Looking more and more like I was right when I said we will be still in this price range towards the end of 2024
I just don’t see a catalyst right now that will move the price up.
Collaboration with other businesses or who ever will not cut it.
Paid basher? Lolololol
I bet you believe in market signals like 911 too.
The Easter Bunny?
I said show me...not talk for others...and this I already know, resident paid bashers rarely ever leave...
Coastar Therapeutics is a start up that got some initial seed money from an investor. I wonder what value they add to SHMN or are they looking to get some investment cash from SHMN.
Phase 1 was announced over a year ago, topicals, the easiest thing to manufacture. I wonder what year that will be completed. Phase 2 and 3 might be done in our lifetime....
You know exactly what i'm talking about. So do members of this board. If anyone doubts it, say something he doesn't like then prepare for nasty messages and negative posts on any stock you post on.
Like I said, classic board bully.
I'm here to stay.
what stocks do I bash, show me....
and numerous times you have no idea what your talking about....funny you always fail to mention this, like it doesn't exist.
https://www.globenewswire.com/news-release/2023/10/10/2757629/0/en/SOHM-Collaborates-with-University-of-Arizona-Center-for-Innovation-to-Advance-ABBIE-a-Groundbreaking-Non-Viral-Gene-Editing-Technology.html
And you have no idea how Dr Auguilar retained ABBIE from Kiromic along with all the problems the CEO was having at the time....as I told you before, contact Kiromic and inquire.
And another thing you fail to mention is how far this science has come since then and where it's going.
some entertainment when you were in a flip...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173053796
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172992391
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173031956
I've said it numerous times, ABBIE is 8-10 year old tech. It's gone through a few companies before and no one went with it. There's a reason it landed with a OTC Pink Sheet company like SHMN.
$SHMN: I can't repeat this ENOUGH...
Company needs to up the Marketing Ante on their peer reviewed results..
Genentech spent ~3Billion on AVASTIN [one of the use cases was for Wet AMD].
They also got sued B/C AVASTIN performed horribly in breast cancer for women.
All of the above was W/O the ability nor benefit of gene-Editing nor feedback from reading back edited DNA via NextGEN Seq.
There are companies out there that will THROW $100's of Millions, now that CRISPR is FDA approved.
No more MoUs & LOIs etc...ask for Investment & Committed POs.
Have a Good Weekend.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174227148
The "big reveal" really has the investors in a frenzy. 0 volume in 2 days.
Well since you bash stocks, this applies to you as well.
sure seems like you do...
it's not curious at all that those that bash stocks end up getting their stocks bashed.....
funny how they don't like it...
I couldn't care less about what you think, much less explaining anything to you.
so tell me, why is SHMN the only stock you bash ?
$SHMN: HL: Anyone with access to SoHM...Please pass this on to Aguilar & Gallegos...ASAP
1. Electroporation alters Phenotypes & also does NOT offer the highest yields to
a. Cell Health
b. Maximizing Payload ["Viral Vector"]
c. Efficiency & Yield of Payload Delivery
Have you looked at cutting edge alternatives to Electroporation? Why constrain yourself to Old-Tech?
Maybe get a FREE TRIAL [for data generation from👇️]
https://www.cellfebiotech.com/how-it-works/
I have NO affiliation to 👆️
2. If you're using a FACS type cell sorter [per your poster] for CD34, then you would be prone to a certain % of error due to
Phenotype changes.
If you need to know who I am...we'll talk thro' Julio M Clark.
And Pls...F*ing publish a Hi-RES POSTER of what you presented at AACR! WTF is Barron trying to hide here!
WTF is your mkt-ing dept doing? Twiddling thumbs?
Board bullies hate when they can't follow you to another board to trash your stocks. They also hate when they can't send you nasty messages.
It's curious that the person that hates bashers so much has no issues bashing other stocks of people that disagree with them. That post history works both ways...
Masters? Good God, put the kool aid down.
LOL !
What's funny is living rent free in your head.... LOL
"Why are you here?" Then post nonsense that notifies me and brings me to the board....
so something is funny that you have no idea of what you are laughing at ?
par for the course....
Hopefully attending DCAT proves beneficial to the co as well.....
I suspect that most contributors to this board have a good sense of what was covered during the preso; I'm hoping that they can capitalize on the momentum from AACR and share it with a broader audience.
New tweet, I don't why it was tweeted today PR is from April 1
We're teaming up with Coastar Therapeutics to transform the way we edit genes using carriers from red blood cell membranes.
— SOHM, Inc. (@sohminc) April 12, 2024
Click through to the press release: https://t.co/w6DjjgehJy#Biotech #GenomeEditing $SHMN #SOHMPress pic.twitter.com/mEgPCVo46I
Maybe I'm just assuming, but I think I know what they presented, not sure what more they could say. They didn't say how it was received ? This Tweet satisfied me, but further discussion would be welcomed. They hinted it was coming....
SOHM, Inc.
@sohminc
We’re thrilled to announce that our presentation at #AACR was met with an exceptional reception. It was an honor to showcase our technology to esteemed researchers and leaders in the biotech industry.
The overwhelming interest and impact generated by our innovation have been truly remarkable.
Stay tuned for more updates following the conclusion of the conference.
$SHMN
According to this statement, things went very well, I guess we will find out in coming weeks/ months.
Regardless, they chose SHMN to establish a distributive presence in the US. What's in it for Sohm remains to be seen.
$SHMN: MDP: One of us seems to have SUCCESSFULLY convinced ourselves that he/She is a EXPERT at DNA Science, FDA, Pharma Cos ....etc ..
The other one has a track record of being an exec in afore mentioned Co's in CA.
I totally agree that they'd be screaming about a signed deal (as well they should).
I'm looking for that middle ground between announcing a signed deal and meaningless pump. They've announced that they were presenting, but then didn't discuss what they presented, how it was received, or put it into terms of how it may benefit the company.
I'd love to see them use this as an opportunity to describe what they spoke about (without getting too far into the weeds) to create perceived value around ABBIE without resorting to pumpy "there's an LOI to investigate the possibility of a partnership at some point in the future" type stuff. Call it a substantive pump, if you will.
With a fully reporting company, a PR is just that - an announcement to the press about *something*. It need not have direct revenue implications, or specifics. It's generally just fluffy good news.
With a non-reporting company, it has to do double duty - announce disclosure that would normally go into an 8-k, but also do the good news reporting.
While most pinks swing waaaaaay too far toward the fluff end of the spectrum and dive into pumpy bullshit, I think SHMN would benefit from sharing a bit more good news (albeit substantive good news).
Well, you successfully misunderstood everything that I posted. Good job.
$SHMN:MDP: You're running too many ASSUMPTIONS... just pure B.S & guessing!
1. Stallion Labs chose $SHMN as their SOLE distributor in N.America (that's a huge mkt)
2. Vol & Vol discounts are a Non-Issue. You need to check out the company (Stallion Labs). They'll provide both,
3. Medical Facility? $SHMN PR'd in Dec '23 that they've been REGISTERED with the U.S. FDA as both mfg & distribution facility.
So it's a NON-ISSUE!
The issues that I (&others) have are:-
1. Need Ms. Jacob to be Pro-Active & get the website updated, as a real co. with RESEARCH FACILITIES!
I believe that's ONE of her core responsibilities
2. Barron & Tony need to update S/Hs on sales & mkt initiatives. I believe Tony's core responsibility is sales (subset of Finance)
3. As was obvious Dr. Aguilar & Gallegos have been grinding away. Thank you to both! And Aguilar...looks to be working on the mkt too!
We're past the '90' day review period. So it's TIME to REVIEW PERFORMANCE!
This is NOT the FEDERAL GOVT!
Stallion Labs has a presence in the US for any of their products since 2009? That's news to Stallion Labs....
They really picked a powerhouse marketing machine in SHMN. Can't even get a website up or keep their self touted Amazon store open...
https://www.stallionlabs.com/international-presence.php
I think your confusing the crap you used to pump that are all worthless now to a much better company with a product that is real....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173031956
bash all you want, no one is buying it...
If Stallion Labs was already selling their product direct in the US to customers, why do they need SHMN? They wouldn't.
No "real" investors are going to touch a alternative reporting OTC stock without audited financials.
SHMN lives in the OTC, they only will get flippers and traders down here.
you really are an expert...lol....
Stallion labs has been manufacturing Levetiracetam since 2009. In 15 years they should already have a large market share.
It is my understanding SHMN now has the exclusive rights to distribute the Stallion brand of the drug to the share of the market Stallion has already established. I also believe that if Stallion thought SHMN didn't have the distribution capabilities they wouldn't have struck an exclusive deal with them to do so.
You don't think that if anything came from it that amounts to a signed deal it would be PR'd and shouted from the roof tops ?
imo Seeking Alpha type pumps can work, they could bring in more flippers, what I want to see is actual investors....
With the PR's we already had, along with engaging IBN to spread the word, and X, it isn't working, that's for sure.
The company has retained Investor Business Network (IBN) for its public relations activities, and our basic corporate profile is live throughout its network. Here are a few links:
— SOHM, Inc. (@sohminc) August 28, 2023
InvestorBrandNetwork (https://t.co/0ffht9X0ph)
NetworkNewsWire (https://t.co/Oar1lUxkQq)
BioMedWire…
Yes Medical Facility. You know, where you have to get prescription drugs.... hospitals, medical centers, pharmacies...
Update their own website at a bare minimum - I would think this would be front page material, but its got to at least appear on their PR & Blog sections (neither of which have been updated since January). Flood the channel with PRs about the preso, and anything good that came from it. Try to find one or more investor focused websites to do a fluffy story (Seeking Alpha types). Posting several summaries across multiple socials.
Just hoping to see that the word is being spread as far and wide as possible, both as a means to increase investor awareness and with a secondary impact on the sales channel.
a medical facility ?
What could SOHM possibly offer a medical facility to switch from their current supplier of Levetiracetam to SHMN's brand? It won't be price since the other established provider has volume and can discount the cost.
I sent an message to IR just 15 min ago saying exactly that in so many words. I'm looking at this as a 3rd/ 4th qtr event ( ABBIE ) that will really affect the pps, but like you said I expected much more interest now.
What we don't know is what is cooking behind closed doors, Japan, DCAT ETC.....they already gave us guidance for a nice 1st qtr.
IR can't disclose " possible " deals/ orders prematurely, at least I for one don't want that.
Let me ask, what do you suggest IR doing as far as " going to town " ?
I was simple asking a question what last years fins have to do with it...
What I am pointing out (so that there won't be a huge disappointment, like Brainwise, when sales from Levetiracetam are no where near what we hope they would be), is that based on current revenues (the fins based on Sohm's world wide distribution abilities to date ) the SOHM distribution market is very very very small compared to it's competitors.
So, don't expect huge market penetration.( I would love the company to prove me wrong).
But at least it is a start to a new beginning.
Followers
|
482
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
65763
|
Created
|
06/10/09
|
Type
|
Free
|
Moderators Myth MDPennyPlayer |
Website: http://www.sohm.com
TWITTER FEED: https://twitter.com/sohminc?lang=en
FACEBOOK FEED: https://www.facebook.com/sohminc/
PRESS RELEASES (SOHM Website): https://www.sohm.com/category/press-releases/
NVSOS: http://nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=DraWvY7hzMLlBgmKhjdRSQ%253d%253d&nt7=0
NVSOS ACTIONS/AMENDMENTS: http://nvsos.gov/SOSEntitySearch/corpActions.aspx?lx8nvq=DraWvY7hzMLlBgmKhjdRSQ%253d%253d&CorpName=SOHM%2c+INC.
Contact info.
Phone: (714) 522-6700
Address:
4195 Chino Hills Pkway
Ste 675
Chino Hills, CA 91709
Email: info@sohm.com
SHMN RECENT NEWS
SOHM Announces Its Acquisition of ABBIE, a World-Class Gene-Editing Platform Which Can Deliver Genetic Payloads Using Non-Viral Vectors
https://www.globenewswire.com/news-release/2023/09/26/2749662/0/en/SOHM-Announces-Its-Acquisition-of-ABBIE-a-World-Class-Gene-Editing-Platform-Which-Can-Deliver-Genetic-Payloads-Using-Non-Viral-Vectors.html
SOHM Collaborates with University of Arizona Center for Innovation to Advance ABBIE, a Groundbreaking Non-Viral Gene-Editing Technology
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |